Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation.

[1]  Sarfaraz Niazi,et al.  Impurities in New Drug Products , 2016 .

[2]  C. Robic,et al.  The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update , 2014, Critical reviews in toxicology.

[3]  J. Heverhagen,et al.  Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis , 2014, Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.

[4]  S. Jimenez,et al.  Induction of a type I interferon signature in normal human monocytes by gadolinium‐based contrast agents: comparison of linear and macrocyclic agents , 2014, Clinical and experimental immunology.

[5]  M. Port,et al.  Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  V. Runge,et al.  MRI contrast agents: Basic chemistry and safety , 2012, Journal of magnetic resonance imaging : JMRI.

[7]  B. Wagner,et al.  Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis. , 2012, Radiology.

[8]  M. Port,et al.  Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide , 2012, British journal of pharmacology.

[9]  M. Rehman,et al.  Stimulation of Fibroblast Proliferation by Insoluble Gadolinium Salts , 2011, Biological Trace Element Research.

[10]  Arthur E. Martell,et al.  Critical Stability Constants , 2011 .

[11]  A. Abu-Alfa,et al.  Nephrogenic systemic fibrosis and gadolinium-based contrast agents. , 2011, Advances in chronic kidney disease.

[12]  M. Port,et al.  Comparative In Vivo Dissociation of Gadolinium Chelates in Renally Impaired Rats: A Relaxometry Study , 2011, Investigative radiology.

[13]  J. Varani,et al.  Fibroblast Response to Lanthanoid Metal Ion Stimulation: Potential Contribution to Fibrotic Tissue Injury , 2011, Biological Trace Element Research.

[14]  S. Morcos.  Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far? , 2011, European Radiology.

[15]  J. Varani,et al.  Fibroblast Response to Gadolinium: Role for Platelet-Derived Growth Factor Receptor , 2010, Investigative radiology.

[16]  C. Anderson,et al.  The biodistribution of [153Gd]Gd‐labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice , 2010, Magnetic resonance in medicine.

[17]  Kui Wang,et al.  Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells , 2010, JBIC Journal of Biological Inorganic Chemistry.

[18]  C. Robic,et al.  Role of thermodynamic and kinetic parameters in gadolinium chelate stability , 2009, Journal of magnetic resonance imaging : JMRI.

[19]  T. Steger-Hartmann,et al.  Impact of Renal Impairment on Long-Term Retention of Gadolinium in the Rodent Skin Following the Administration of Gadolinium-Based Contrast Agents , 2009, Investigative radiology.

[20]  D. Løvhaug,et al.  Effects of gadolinium contrast agents in naïve and nephrectomized rats: Relevance to nephrogenic systemic fibrosis , 2009, Acta radiologica.

[21]  R. Swartz,et al.  Effects of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents on Human Skin in Organ Culture and Human Skin Fibroblasts , 2009, Investigative radiology.

[22]  M. Mack,et al.  Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[23]  T. Frenzel,et al.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions , 2008, European Radiology.

[24]  Hanns-Joachim Weinmann,et al.  Gadolinium‐based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: The role of excess ligand , 2008, Journal of magnetic resonance imaging : JMRI.

[25]  C. Robic,et al.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.

[26]  T. Frenzel,et al.  A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media , 2008, Investigative radiology.

[27]  L. Skov,et al.  Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long‐term persistence in nephrogenic systemic fibrosis , 2007, The British journal of dermatology.

[28]  A. Morisetti,et al.  Toxicological assessment of gadolinium release from contrast media. , 2007, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[29]  S. Morcos.  Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.

[30]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[31]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  Dawn G Goodman,et al.  Best Practices Guideline: Toxicologic Histopathology , 2004, Toxicologic pathology.

[33]  S. Curley,et al.  Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases , 1992, Clinical & Experimental Metastasis.

[34]  P. Bell,et al.  The effect of kupffer cell stimulation or depression on the development of liver metastases in the rat , 2004, Cancer Immunology, Immunotherapy.

[35]  L. Gustafsson,et al.  Basic experimental studies and clinical aspects of gadolinium salts and chelates. , 2006, Cardiovascular drug reviews.

[36]  A. Pałasz,et al.  Toxicological and cytophysiological aspects of lanthanides action. , 2000, Acta biochimica Polonica.

[37]  A. Reid,et al.  Gadolinium Chloride Toxicity in the Rat , 1997, Toxicologic pathology.

[38]  T. Monticello,et al.  Utilization of Electron Probe Microanalysis in Gadolinium-Treated Mice , 1996, Toxicologic pathology.

[39]  S. Arii,et al.  The role of Kupffer cells in the surveillance of tumor growth in the liver. , 1993, The Journal of surgical research.

[40]  P. Wedeking,et al.  Dose-dependent biodistribution of [153Gd]Gd(acetate)n in mice. , 1993, Nuclear medicine and biology.

[41]  M. W. Flye,et al.  Kupffer cell blockade increases mortality during intra-abdominal sepsis despite improving systemic immunity. , 1990, Archives of surgery.

[42]  Analysis of Repeated-Measures Designs , 1989 .

[43]  E. Smith.  Analysis of repeated measures designs. , 1987, The Journal of pediatrics.